JP2008538586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538586A5 JP2008538586A5 JP2008507992A JP2008507992A JP2008538586A5 JP 2008538586 A5 JP2008538586 A5 JP 2008538586A5 JP 2008507992 A JP2008507992 A JP 2008507992A JP 2008507992 A JP2008507992 A JP 2008507992A JP 2008538586 A5 JP2008538586 A5 JP 2008538586A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- compound
- composition
- nac amide
- isomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 94
- 150000001875 compounds Chemical class 0.000 claims 48
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 38
- 238000000034 method Methods 0.000 claims 30
- 230000008569 process Effects 0.000 claims 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 17
- 238000001914 filtration Methods 0.000 claims 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 15
- 238000001035 drying Methods 0.000 claims 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 10
- 238000002156 mixing Methods 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- 229910001868 water Inorganic materials 0.000 claims 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 8
- 150000008064 anhydrides Chemical class 0.000 claims 8
- 239000002105 nanoparticle Substances 0.000 claims 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 6
- 239000003963 antioxidant agent Substances 0.000 claims 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 5
- 229910021529 ammonia Inorganic materials 0.000 claims 5
- 235000019270 ammonium chloride Nutrition 0.000 claims 5
- 230000003078 antioxidant effect Effects 0.000 claims 5
- -1 lithium aluminum hydride Chemical compound 0.000 claims 5
- 235000017281 sodium acetate Nutrition 0.000 claims 5
- 239000001632 sodium acetate Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 159000000021 acetate salts Chemical class 0.000 claims 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 4
- 230000008859 change Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 239000012280 lithium aluminium hydride Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 4
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 claims 4
- 150000003573 thiols Chemical class 0.000 claims 4
- 108010024636 Glutathione Proteins 0.000 claims 3
- 229960003180 glutathione Drugs 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 208000019838 Blood disease Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000008520 organization Effects 0.000 claims 2
- 238000012261 overproduction Methods 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001376 precipitating effect Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 230000008354 tissue degradation Effects 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- OYPOYMPGFACTLO-RGVONZFCSA-N (2r)-2-amino-3-[[(2r)-2,3-diamino-3-oxopropyl]disulfanyl]propanamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)[C@@H](N)CSSC[C@H](N)C(N)=O OYPOYMPGFACTLO-RGVONZFCSA-N 0.000 claims 1
- PFRXZICTHLYYGK-UHFFFAOYSA-N 2,5,7-trimethoxynaphthalene-1,4-dione Chemical compound C1=C(OC)C=C2C(=O)C(OC)=CC(=O)C2=C1OC PFRXZICTHLYYGK-UHFFFAOYSA-N 0.000 claims 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- OYPOYMPGFACTLO-XWJKVJTJSA-N Cl.Cl.NC(=O)[C@H](N)CSSC[C@@H](N)C(N)=O Chemical compound Cl.Cl.NC(=O)[C@H](N)CSSC[C@@H](N)C(N)=O OYPOYMPGFACTLO-XWJKVJTJSA-N 0.000 claims 1
- 201000000054 Coronary Restenosis Diseases 0.000 claims 1
- 206010056489 Coronary artery restenosis Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000004449 DNA Virus Infections Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 claims 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000009341 RNA Virus Infections Diseases 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 101710108790 Stromelysin-1 Proteins 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- UDHSAWHYRXHQJP-HNCPQSOCSA-N methyl (2R)-2-amino-3-phenylmethoxypropanoate hydrochloride Chemical compound Cl.COC(=O)[C@H](N)COCC1=CC=CC=C1 UDHSAWHYRXHQJP-HNCPQSOCSA-N 0.000 claims 1
- QVJDVOZRQMIIHP-PPHPATTJSA-N methyl (2r)-2-amino-3-benzylsulfanylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CSCC1=CC=CC=C1 QVJDVOZRQMIIHP-PPHPATTJSA-N 0.000 claims 1
- QVJDVOZRQMIIHP-HNCPQSOCSA-N methyl (2s)-2-amino-3-benzylsulfanylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CSCC1=CC=CC=C1 QVJDVOZRQMIIHP-HNCPQSOCSA-N 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920000962 poly(amidoamine) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- NGDIAZZSCVVCEW-UHFFFAOYSA-M sodium;butyl sulfate Chemical compound [Na+].CCCCOS([O-])(=O)=O NGDIAZZSCVVCEW-UHFFFAOYSA-M 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000133 toxic exposure Toxicity 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67356105P | 2005-04-21 | 2005-04-21 | |
| US70596705P | 2005-08-05 | 2005-08-05 | |
| PCT/US2006/015548 WO2006116353A2 (en) | 2005-04-21 | 2006-04-21 | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538586A JP2008538586A (ja) | 2008-10-30 |
| JP2008538586A5 true JP2008538586A5 (enExample) | 2009-07-09 |
Family
ID=37215387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507992A Pending JP2008538586A (ja) | 2005-04-21 | 2006-04-21 | 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20090234011A1 (enExample) |
| EP (1) | EP1877044A4 (enExample) |
| JP (1) | JP2008538586A (enExample) |
| KR (1) | KR20080028357A (enExample) |
| AU (1) | AU2006238888A1 (enExample) |
| CA (1) | CA2606053A1 (enExample) |
| IL (1) | IL186684A0 (enExample) |
| RU (1) | RU2007143040A (enExample) |
| WO (1) | WO2006116353A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE552260T1 (de) | 1999-01-25 | 2012-04-15 | Nat Jewish Health | Substituierte porphyrine und deren therapeutische verwendung |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| KR20080028357A (ko) | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드) |
| EP1968609A4 (en) * | 2005-12-20 | 2010-06-09 | Silamed Inc | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS |
| ZA200902203B (en) * | 2006-10-23 | 2010-08-25 | Mental Health Res Inst Of Vict | Combination therapy |
| US20080146579A1 (en) * | 2006-12-15 | 2008-06-19 | N.V. Nutricia | Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore |
| WO2008121171A1 (en) * | 2007-01-12 | 2008-10-09 | Cornell Research Foundation, Inc. | Adenylyl cyclases as novel targets for antibacterial interventions |
| US9095578B2 (en) * | 2007-01-12 | 2015-08-04 | Cornell Research Foundation, Inc. | Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens |
| IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| CN102088965B (zh) * | 2008-05-13 | 2013-05-08 | 根梅迪卡治疗公司 | 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用 |
| EP2732817B1 (en) * | 2008-05-23 | 2016-08-24 | National Jewish Health | A compound for use in treating injury associated with exposure to phosgene or chlorine gas |
| US8575217B2 (en) * | 2009-03-16 | 2013-11-05 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| CN102421424A (zh) * | 2009-03-16 | 2012-04-18 | 根梅迪卡治疗公司 | 用于治疗代谢性疾病的组合疗法 |
| JP2011088829A (ja) * | 2009-10-20 | 2011-05-06 | Chube Univ | 発癌毒性の評価方法及び発癌予防・治療剤 |
| TWI535440B (zh) | 2009-10-26 | 2016-06-01 | Ｌｇ生命科學有限公司 | 包括吲哚化合物之醫藥組成物 |
| EP2614821B1 (en) | 2010-09-06 | 2016-11-09 | SNU R & DB Foundation | Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof |
| FR2964967A1 (fr) * | 2010-09-17 | 2012-03-23 | Exsymol Sa | Peptidomimetiques derives de la methionine et leur utilisation dans la protection des mitochondries des cellules cutanees |
| JP5854592B2 (ja) * | 2010-11-09 | 2016-02-09 | 丸善製薬株式会社 | 抗酸化剤及び抗炎症剤 |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| CA2826602C (en) | 2011-02-04 | 2019-06-11 | Hough Ear Institute | Methods for treating brain injury |
| WO2013138744A1 (en) * | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| WO2013152076A1 (en) * | 2012-04-04 | 2013-10-10 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hypertension |
| US20150148423A1 (en) | 2012-04-26 | 2015-05-28 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
| CA3078006C (en) | 2012-07-10 | 2022-04-26 | Xpd Holdings, Llc | Stabilized multi-functional antioxidant compounds and methods of use |
| EP3019164B1 (en) * | 2013-07-10 | 2020-08-19 | Glenn A. Goldstein | Use of n-acetylcysteine amide in the treatment of penetrating head injury |
| LT3066089T (lt) | 2013-11-08 | 2020-02-25 | Promentis Pharmaceuticals, Inc. | Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai |
| US20150209309A1 (en) * | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc | Naca for the treatment of chronic or acute cognitive dysfunction |
| WO2015112715A1 (en) * | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Naca for the treatment of chronic or low impact brian trauma |
| US20170049727A1 (en) * | 2014-02-12 | 2017-02-23 | Glenn A. Goldstein | Use of N-Acetylcysteine Amide in the Treatment of Acquired Immune Deficiency Syndrome and HIV Infection |
| WO2016044314A1 (en) * | 2014-09-15 | 2016-03-24 | Sound Pharmaceuticals Incorporated | Methods and compositions for treating psychotic disorders |
| RU2711913C2 (ru) * | 2014-11-07 | 2020-01-24 | Дзе Джонс Хопкинс Юниверсити | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом |
| US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| EP3250196A4 (en) | 2015-01-27 | 2018-09-26 | Florengale, LLC | Healing topical composition |
| WO2016197089A1 (en) * | 2015-06-05 | 2016-12-08 | Goldstein Glenn A | Use of n-acetylcysteine amide in the treatment of acetaminophen overdose |
| WO2017122120A1 (en) | 2016-01-11 | 2017-07-20 | Pledpharma Ab | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| EP3448378B1 (en) * | 2016-04-29 | 2024-04-17 | Ophirex, Inc. | Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| CN111386255B (zh) | 2017-09-20 | 2021-11-23 | 纳崔泰制药有限公司 | 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法 |
| US20240368072A1 (en) * | 2017-09-20 | 2024-11-07 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives |
| US20240342118A1 (en) * | 2017-09-20 | 2024-10-17 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US20240217927A1 (en) * | 2017-11-09 | 2024-07-04 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190135741A1 (en) * | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| KR102145929B1 (ko) * | 2017-11-28 | 2020-08-20 | 주식회사 셀투인 | 실시간 글루타치온 측정을 통한 치료용 세포의 품질 측정 방법 |
| CU20200106A7 (es) | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| US11497758B2 (en) | 2018-11-15 | 2022-11-15 | Samuel L. Shepherd | Method of treating oxidative stress due to radiation exposure |
| US11766413B2 (en) | 2019-01-11 | 2023-09-26 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) |
| US12245998B2 (en) * | 2019-01-11 | 2025-03-11 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis |
| CN109758581A (zh) * | 2019-02-14 | 2019-05-17 | 上海市东方医院（同济大学附属东方医院） | 一种抗氧化磁性氧化铁纳米颗粒及其制备方法 |
| EP3984993A4 (en) * | 2019-06-13 | 2023-07-19 | Shanghai Kechow Pharma, Inc. | USE OF AMINOTHIOL COMPOUNDS AS CRANIAL NERVE OR CARDIAC PROTECTIVE AGENT |
| AU2020407239B2 (en) * | 2019-12-18 | 2025-11-27 | Burke Neurological Institute | Methods of treating brain disorders |
| WO2021151044A1 (en) * | 2020-01-24 | 2021-07-29 | Nacuity Pharmaceuticals, Inc. | Prodrug for the treatment of disease and injury of oxidative stress |
| WO2021252378A1 (en) * | 2020-06-08 | 2021-12-16 | Nacuity Pharmaceuticals, Inc. | Prevention or treatment of covid-19 |
| US20230263725A1 (en) * | 2020-07-09 | 2023-08-24 | Beyond Barriers Therapeutics, Inc. | Intranasal administration of an antioxidant compound for treating coronavirus infection |
| AU2021321510A1 (en) * | 2020-08-06 | 2023-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Oleylcysteineamide or derivatives thereof and their use in therapy |
| EP3960168A1 (en) * | 2020-08-28 | 2022-03-02 | Université de Genève | Compositions and methods comprising d-cysteine or a derivative thereof |
| CN112602724B (zh) * | 2020-12-21 | 2021-09-24 | 上海汉今医疗科技有限公司 | 一种感染性医疗废物消毒液及其制备方法 |
| AU2022204064A1 (en) | 2021-07-16 | 2023-02-02 | Samuel L. Shepherd | Method of treating oxidative stress due to radiation exposure |
| CN115449065B (zh) * | 2022-09-21 | 2023-09-22 | 中南大学湘雅医院 | 一种nac改性血液净化膜及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US5691380A (en) | 1995-06-29 | 1997-11-25 | The Procter & Gamble Company | Stable n-acetylcysteine compositions and methods for treating human skin therewith |
| US5733535A (en) * | 1995-10-25 | 1998-03-31 | The Procter & Gamble Co. | Topical compositions containing N-acetylcysteine and odor masking materials |
| US5962421A (en) * | 1996-05-16 | 1999-10-05 | Zambon, S.A. | Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases |
| US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6420429B1 (en) * | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6719969B1 (en) | 1999-08-09 | 2004-04-13 | The Regents Of The University Of Michigan | Treatment of liver disease and injury with CXC chemokines |
| JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| US6623754B2 (en) * | 2001-05-21 | 2003-09-23 | Noveon Ip Holdings Corp. | Dosage form of N-acetyl cysteine |
| WO2003016551A2 (en) * | 2001-08-16 | 2003-02-27 | Boyce Thompson Institute For Plant Research, Inc. | Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof |
| WO2004012652A2 (en) * | 2002-08-02 | 2004-02-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| WO2004095926A2 (en) * | 2003-04-28 | 2004-11-11 | Monsanto Technology, Llc | Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield |
| JP2008538566A (ja) * | 2005-04-21 | 2008-10-30 | グレン エー． ゴールドスタイン， | 環境ストレスに対する植物の抵抗性および耐性を促進するためのｎ−アセチルシステインアミド（ｎａｃアミド） |
| KR20080028357A (ko) * | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드) |
| JP2008536524A (ja) | 2005-04-21 | 2008-09-11 | グレン エー． ゴールドスタイン， | 不妊に関連する酸化ストレス治療のためのｎ−アセチルシステインアミド（ｎａｃアミド） |
-
2006
- 2006-04-21 KR KR1020077027031A patent/KR20080028357A/ko not_active Withdrawn
- 2006-04-21 US US11/912,293 patent/US20090234011A1/en not_active Abandoned
- 2006-04-21 RU RU2007143040/15A patent/RU2007143040A/ru unknown
- 2006-04-21 CA CA002606053A patent/CA2606053A1/en not_active Abandoned
- 2006-04-21 EP EP06751310A patent/EP1877044A4/en not_active Withdrawn
- 2006-04-21 JP JP2008507992A patent/JP2008538586A/ja active Pending
- 2006-04-21 AU AU2006238888A patent/AU2006238888A1/en not_active Abandoned
- 2006-04-21 WO PCT/US2006/015548 patent/WO2006116353A2/en not_active Ceased
-
2007
- 2007-10-16 IL IL186684A patent/IL186684A0/en unknown
-
2010
- 2010-01-12 US US12/686,106 patent/US8354449B2/en not_active Expired - Fee Related
- 2010-02-17 US US12/707,092 patent/US8937099B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538586A5 (enExample) | ||
| RU2007143040A (ru) | Амид n-ацетилцистеина (амид nac) в лечении заболеваний и состояний, связанных с окислительным стрессом | |
| US9314532B2 (en) | Drug delivery vehicle | |
| EP2061749B1 (en) | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate | |
| JP2020180153A (ja) | 真菌感染症の治療方法 | |
| EP2641605B1 (en) | Polymer derivative of cytidine metabolism antagonist | |
| CN104586859A (zh) | 喹硫平的氨基酸缀合物、其制备和使用方法 | |
| JP2011006428A5 (enExample) | ||
| US9572801B2 (en) | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | |
| CN1708540A (zh) | 喜树碱的高分子衍生物 | |
| TW200901964A (en) | Pharmaceutical formulations containing lipoic acid derivatives | |
| EP2623495B1 (en) | Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate | |
| AU2018392985A1 (en) | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases | |
| WO2022022354A1 (zh) | 聚乙二醇偶联药物增效剂、其制备方法及用途 | |
| AU2003228593A1 (en) | Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt | |
| US8304565B2 (en) | PEG-lipid conjugates for liposomes and drug delivery | |
| CA2782224A1 (en) | Azilsartan organic amine salts, preparation method and use thereof | |
| KR20140097108A (ko) | 전구약물로서의 펜타미딘 아미독심 산 에스테르류 및 이의 약물로서의 용도 | |
| JP2022120034A (ja) | 吸入粉末剤、その評価方法及びその用途 | |
| AU3943395A (en) | A chitosan polymer having a specific degree of acetylation | |
| US11524078B2 (en) | Water-soluble macromolecular derivative of Venetoclax | |
| KR102256453B1 (ko) | 소수성 약물 전달용 신규한 폴리머계 하이드로트로프 | |
| TW201113525A (en) | Methods for diagnosing diabetes and determining effectiveness of treatments | |
| CN101367775B (zh) | 一种绕丹宁衍生物、其制备方法及其应用 | |
| JP4874985B2 (ja) | 免疫調節化合物による出血性ウイルス感染の治療又は予防 |